AM  Vol.6 No.6 , June 2015
An Optimal Control Approach to HIV Immunology
ABSTRACT
This paper introduces a mathematical model which describes the dynamics of the spread of HIV in the human body. This model is comprised of a system of ordinary differential equations that involve susceptible cells, infected cells, HIV, immune cells and immune active cells. The distinguishing feature in the proposed model with respect to other models in the literature is that it takes into account cells that represent two distinct mechanisms of the immune system in the defense against HIV: the non-HIV-activated cells and the HIV-activated cells. With a view at minimizing the side effects of a treatment that employs a drug combination designed to attack the HIV at various stages of its life cycle, we introduce control variables that represent the infected patient’s medication. The optimal control rule that prescribes the medication for a given time period is obtained by means of Pontryagin’s Maximum Principle.

Cite this paper
Arruda, E. , Dias, C. , de Magalhães, C. , Pastore, D. , Thomé, R. and Yang, H. (2015) An Optimal Control Approach to HIV Immunology. Applied Mathematics, 6, 1115-1130. doi: 10.4236/am.2015.66102.
References
[1]   Eisele, E. and Siliciano, R. (2012) Redefining the Viral Reservoirs That Prevent HIV-1 Eradication. Immunity, 37, 377-388.
http://dx.doi.org/10.1016/j.immuni.2012.08.010

[2]   Finzi, D., Blankson, J., Siliciano, J., Margolick, J., Chadwick, K., Pierson, T., Smith, K., Lisziewicz, J., Lori, F., Flexner, C., Quinn, T., Chaisson, R., Rosenberg, E., Walker, B., Gange, S., Gallant, J. and Siliciano, R. (1999) Latent Infection of CD4+ T Cells Provides a Mechanism for Lifelong Persistence of HIV-1, Even in Patients on Effective Combination Therapy. Nature Medicine, 5, 512-517.
http://dx.doi.org/10.1038/8394

[3]   Balamurali, M., Petravic, J., Loh, L., Alcantara, S., Kent, S.J. and Davenport, M.P. (2010) Does Cytolysis by CD8+ T Cells Drive Immune Escape in HIV Infection? The Journal of Immunology, 185, 5093-5101.
http://dx.doi.org/10.4049/jimmunol.1002204

[4]   Nowak, M. and Bangham, C. (1996) Population Dynamics of Immune Responses to Persistent Viruses. Science, 272, 74-79.
http://dx.doi.org/10.1126/science.272.5258.74

[5]   Perelson, A. (2002) Modelling Viral and Immune System Dynamics. Nature Reviews Immunology, 2, 28-36.
http://dx.doi.org/10.1038/nri700

[6]   Siewe, B., Wallace, J., Rygielski, S., Stapleton, J.T., Martin, J., Deeks, S.G. and Landay, A. (2014) Regulatory B Cells Inhibit Cytotoxic t Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after in Vitro Reactivation of HIV Latent Reservoirs. PLoS ONE, 9, e92934.
http://dx.doi.org/10.1371/journal.pone.0092934

[7]   Grégio, J., Caetano, M. and Yoneyama, T. (2009) State Estimation and Optimal Long Period Clinical Treatment of HIV Seropositive Patients. Anais da Academia Brasileira de Ciências, 81, 3-12.
http://dx.doi.org/10.1590/S0001-37652009000100002

[8]   Nowak, M. and May, R. (2000) Virus Dynamics: Mathematical Principles of Immunology and Virology. Oxford University Press, Oxford.

[9]   Perelson, A. and Nelson, P. (1999) Mathematical Analysis of HIV-1 Dynamics in Vivo. SIAM Review, 41, 3-44.
http://dx.doi.org/10.1137/S0036144598335107

[10]   Perelson, A. and Ribeiro, R. (2013) Modeling the Within-Host Dynamics of HIV Infection. BMC Biology, 11, 96.
http://dx.doi.org/10.1186/1741-7007-11-96

[11]   Daugas, E. and Rougier, J. (2005) HAART-Related Nephropathies in HIV-Infected Patients. Kidney International, 67, 393-403.
http://dx.doi.org/10.1111/j.1523-1755.2005.67096.x

[12]   Sreenivasan, S. and Dasegowda, V. (2010) Adverse Effects after HAART Initiation in Resource-Limited Settings: A Prospective Study from Mysore, India. The Journal of Infection in Developing Countries, 4, 750-753.
http://dx.doi.org/10.3855/jidc.934

[13]   Torres, R. and Lewis, W. (2014) Aging and HIV/AIDS: Pathogenetic Role of Therapeutic Side Effects. Laboratory Investigation, 94, 120-128.
http://dx.doi.org/10.1038/labinvest.2013.142

[14]   Kirk, D. (1970) Optimal Control Theory: An Introduction. Prentice-Hall, Englewood Cliff.

[15]   Adkinson Jr., N.F., Bochner, B.S., Busse, W.W., Holgate, S.T., Lemanske, R.F. and Simons, F.E. (2003) Middleton’s Allergy—Principles and Practice. Vol. 1, Mosby, Philadelphia.

[16]   Kreysig, E. (1978) Introductory Functional Analysis with Applications. Wiley, New York.

[17]   Dorf, R.C. and Bishop, R.H. (2001) Modern Control Systems. 9th Edition, Prentice Hall, Upper Saddle River.

[18]   Lewis, F. and Syrmos, V. (1995) Optimal Control. John Wiley and Sons, New York.

[19]   Pontryagin, L., Boltyanskij, V., GamKrelidze, R. and Mishchenko, E. (1961) The Mathematical Theory of Optimal Processes. Interscience Publishers, New York.

[20]   Mclean, A. (2013) Infectious Disease Modeling. In: Kanki, P. and Grmes, D.J., Eds., Infectious Diseases, Springer, New York, 99-115.
http://dx.doi.org/10.1007/978-1-4614-5719-0_5

[21]   Chun, T., Carruth, L., Finzi, D., Shen, X., Digiuseppe, J., Taylor, H., Hermankova, M., Chadwick, K., Margolick, J., Kuo, Y., Brookmeyer, R., Zeiger, M., Barditch-Crovo, P. and Siliciano, R. (1997) Quantification of Latent Tissue Reservoirs and Total Body Viral Load in HIV-1 Infection. Nature, 387, 183-188.
http://dx.doi.org/10.1038/387183a0

[22]   Ho, P., Neumann, A., Perelson, A., Chew, W., Leonardo, J. and Markowitz, M. (1995) Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection. Nature, 373, 123-126.
http://dx.doi.org/10.1038/373123a0

[23]   Lafeuillade, A., Poggi, C., Profizi, N., Tamalet, C. and Costes, O. (1996) Human Immunodeficiency Virus Type 1 in Lymph Nodes Compared with Plasma. Journal of Infectious Diseases, 174, 404-407.
http://dx.doi.org/10.1093/infdis/174.2.404

 
 
Top